COMMUNIQUÉS West-GlobeNewswire
-
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
18/06/2026 -
BiomX Provides Update on Defense Technology Portfolio and Growth Strategy
18/06/2026 -
SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies
18/06/2026 -
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
18/06/2026 -
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
18/06/2026 -
FamilyWell Health Launches Menopause Hub, Setting the Standard for Behavioral Health in Midlife Care
18/06/2026 -
New Research from Marius Pharmaceuticals Reveals Major Men's Health Awareness Gap: 65% Have Never Had Their Testosterone Levels Tested
18/06/2026 -
FDA Approves First Single-Dose Generic Treatment for Influenza
18/06/2026 -
International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress
18/06/2026 -
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
18/06/2026 -
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
18/06/2026 -
SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets
18/06/2026 -
NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested
18/06/2026 -
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
18/06/2026 -
Earth Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026
18/06/2026 -
Lite Strategy Leads Strategic Investment in LitVM
18/06/2026 -
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
18/06/2026 -
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
18/06/2026 -
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
18/06/2026
Pages